Merck partners with Agenus for cancer immunotherapies
Agenus Inc. (developing checkpoint modulators, heat-shock protein vaccines, and adjuvants for cancer and infectious diseases) agreed to use its 4-Antibody Retrocyte Display platform to discover fully human antibodies against two of Merck & Co. Inc.’s immune checkpoint targets for cancer. Merck gets rights to develop and sell the resulting compounds.
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com